NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

Silexion Therapeutics Corp (SLXNW) Stock Analysis

Silexion Therapeutics Corp (SLXNW) is a stock listed on NASDAQ and quoted in US Dollar.

SLXNW

$0.01

+$0.00 (+23.89%)

Sep 2, 2026 · Market close

This is a derivative instrument — a warrant on Silexion Therapeutics Corp (SLXN) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View SLXN →

Price History

Hover for the daily close. The dotted line marks the period open.

SLXNW Key Statistics

As of Sep 2, 2026
Trading
Open
$0.03
Previous Close
$0.01
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.27

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SLXNW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.66%
2025 (partial year)+0.00%

As of September 2, 2026.

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Visit website →